16 min listen
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
FromBlood Podcast
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
FromBlood Podcast
ratings:
Length:
19 minutes
Released:
Apr 18, 2024
Format:
Podcast episode
Description
In this week's episode, we'll discuss gut microbiota exploitation by CPX-351 in acute myeloid leukemia. Then we'll learn about optimizing anti-myeloma immunity. New research shows that regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation. Finally we'll discuss among pediatric patients with ITP or other autoimmune cytopenias, which ones will go on to develop systemic lupus? Featured Articles: CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasisRegulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantationAntinuclear antibody–associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus
Released:
Apr 18, 2024
Format:
Podcast episode
Titles in the series (100)
Season 1, Episode 2: This episode will explore the consequences of a loss of the interaction between mutant calreticulin and another ER resident protein, and how this may promote myeloproliferative neoplasms, the role of a calcium-induced transcription factor in driving diffu by Blood Podcast